Schrodinger, Inc. (SDGR)
NASDAQ:SDGR
Want to see SDGR full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.59Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights robust top-line momentum (ACV growth of 12%), a large year-over-year surge in drug discovery revenue (~124%), strong product and R&D validation (Ajax acquisition, multiple exits, clinical data), meaningful progress migrating customers to hosted licensing, and an upcoming AI-driven product (Bunsen) expected to increase throughput and long‑term monetization. Offsetting these positives are near-term revenue recognition headwinds from the hosted transition, notable margin compression (software gross margin down 11 points), a steep drop in contribution revenue after a grant completed, and an ongoing net loss ($60M Q1), though management is exercising expense discipline and maintains guidance with a solid cash position (~$406M). On balance, the strategic wins, product momentum, and financial visibility (ACV guidance) materially outweigh the near-term recognition and margin challenges.Company Guidance
Annual Contract Value (ACV) Growth
ACV of $28.4 million in Q1 2026, a 12% increase year-over-year from $25.4 million in Q1 2025. Full-year ACV guidance maintained at $218M–$228M (10%–15% growth). Q2 ACV guide $19M–$23M (excludes contribution ACV).
Strong Drug Discovery Revenue Surge
Drug discovery revenue of $22.9 million in Q1 2026 versus $10.2 million in Q1 2025 — approximately +124% year-over-year, driven by accelerated recognition of deferred revenue from collaboration progress.
Total Revenue and Software Mix
Total revenue of $58.6 million for the quarter. Software revenue was $35.6 million, with hosted revenue contributing $12.1 million (34% of software revenue in Q1 2026 vs 24% in 2025); trailing four-quarter hosted revenue was 27% of software revenue.
Progress on Hosted Licensing Transition
Broad-based growth from usage scale-ups, new customers and new products. Transition to hosted licensing showing early positive conversion dynamics (34% hosted in the quarter, target to reach ~75% hosted over three years), and some multiyear on-premise contracts were converted to hosted ahead of renewal.
Bunsen — Agentic AI Co-Scientist Launch
Announced early access release of Bunsen (agentic AI) this summer. Internal use reported to materially improve productivity and throughput; expected to drive higher utilization of compute-heavy workflows and support throughput-based licensing upside.
Therapeutics & Corporate Transactions Validate Platform
Lilly's announced $2.3 billion acquisition of Ajax Therapeutics (a co-founded company) highlights platform impact; Schrödinger holds ~6% equity in Ajax. Company reports seven major transactions/exits across co-discovered molecules and has realized close to $700 million in cash from equity/BD activities, plus potential milestones up to $5 billion and royalties on 15 programs.
Clinical Progress in Wholly Owned Programs
SGR3515 (WE1 inhibitor) Phase 1: generally well tolerated on intermittent dosing with initial biomarker validation and 65% disease control rate among evaluable patients at doses ≥100 mg. SGR1505 (MORT1 inhibitor): 100% response rate with durable responses in Waldenström's macroglobulinemia; holds FDA Fast Track and Orphan Drug designations.
Expense Discipline and Strong Cash Position
Total operating expenses decreased 4% to $78 million (Q1 2026 vs Q1 2025). Ending cash and marketable securities reported at $406 million. Management expects operating expenses for FY2026 to be less than 2025 and anticipates only ~$10M–$15M of R&D spend to complete clinical activities as those wind down.
SDGR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SDGR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $12.87 | $12.98 | +0.85% |
Feb 25, 2026 | $11.80 | $12.76 | +8.14% |
Nov 05, 2025 | $19.77 | $18.65 | -5.67% |
Aug 06, 2025 | $19.34 | $19.36 | +0.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Schrodinger, Inc. (SDGR) report earnings?
Schrodinger, Inc. (SDGR) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Schrodinger, Inc. (SDGR) earnings time?
Schrodinger, Inc. (SDGR) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SDGR EPS forecast?
SDGR EPS forecast for the fiscal quarter 2026 (Q2) is -0.48.
